by admin | 30 July 2020 | News
New York/London, 30 July 2020 – Tiziana Life Sciences plc (“Tiziana”, AIM: TILS, NASDAQ: TLSA) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious... by admin | 30 July 2020 | News
NEW YORK/LONDON, July 30, 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announced that Kunwar Shailubhai,... by admin | 24 July 2020 | News
London, New York, 24 July 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that it has... by admin | 20 July 2020 | News
New York/London, 20 July 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a US and UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, is pleased to announce the... by admin | 16 July 2020 | News
London, New York, 16 July 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the “Company” or “Tiziana”), a US and UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease... by admin | 16 July 2020 | News
New York/London, July 16, 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, is pleased to announce that it has... by admin | 15 July 2020 | News
New York/London, 15 July 2020 – Tiziana Life Sciences plc (“Tiziana”, AIM: TILS, NASDAQ: TLSA), announces a ratio change to its sponsored Level 3 American Depositary Receipt (“ADR”) programme. Please note that pursuant to the announcement... by admin | 15 July 2020 | News
New York/London, 15 July 2020 – Tiziana Life Sciences plc (“Tiziana”, AIM: TILS, NASDAQ: TLSA), announces a ratio change to its sponsored Level 3 American Depositary Receipt (“ADR”) programme. This corporate action, which is a 2.5 for 1... by admin | 10 July 2020 | News
NEW YORK and LONDON, July 10, 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a clinical stage biotechnology company developing targeted drugs for cancer, inflammatory diseases and COVID-19, today announced an interview with... by admin | 1 July 2020 | News
London, New York, 1 July 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the “Company” or “Tiziana”), a US and UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease... by admin | 29 June 2020 | News
This proprietary inhalation technology for direct delivery of mAbs or other small molecule drugs such as Remdesivir® (Roche) to lungs could potentially be a transformational therapy for developing a rapid treatment for COVID-19 New York/London – 29 June 2020 – Tiziana... by admin | 23 June 2020 | News
London, New York, 23 June 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the “Company” or “Tiziana”), a US and UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease... by admin | 21 June 2020 | News
London, New York, 22 June 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the “Company” or “Tiziana”), a US and UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease... by admin | 19 June 2020 | News
Tiziana Granted First-Ever Patent on a Transformational Technology for Oral Delivery of all Anti-CD3 Monoclonal Antibodies for Treatment of Human Diseases First-ever granted patent on oral administration of anti-CD3 monoclonal antibodies for immunotherapies... by admin | 18 June 2020 | News
London / New York, 18 June 2020 – Tiziana Life Sciences plc (NASDAQ: TLSA / AIM: TILS), the U.S. and U.K. biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, announces Gregor... by admin | 18 June 2020 | News
Tiziana Life Sciences PLC (“Tiziana” or the “Company”) Final Results for the Year Ended 31 December 2019 London / New York 18 June 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), (the “Company” or... by admin | 12 June 2020 | News
Tiziana Life Sciences plc (AIM:TILS) is pleased to announce the agreement of an extension to the current At the Market Sales Agreement with ThinkEquity, a division of Fordham Financial Management, Inc. As previously announced on 15 April 2020, Tiziana Life Sciences... by admin | 4 June 2020 | News
New York/London, 4 June 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, announces that the Chairman of the Company’s Scientific Advisory... by admin | 2 June 2020 | News
The announcement (RNS Number: 6069O) released on 2 June 2020 at 07:00 am stated that 1,498,685 new ordinary shares will be issued yielding £710,843 in cash proceeds, the announcement should have stated the number of shares to be issued is 1,234,399, yielding £578,700... by admin | 2 June 2020 | News
London, New York, 2 June 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the “Company” or “Tiziana”), a US and UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease... by admin | 1 June 2020 | News
FOR IMMEDIATE RELEASE 1 June 2020 Tiziana Life Sciences plc (AIM:TILS) is pleased to announce the appointment of Optiva Securities Limited as its broker with immediate effect. Enquiries: Gabriele Cerrone, Chairman and founder +44 (0)20 7495 2379 Cairn Financial... by admin | 29 May 2020 | News
StemPrintER Outperforms Oncotype DX in analysis with 800+ samples from ER+/HER2- postmenopausal breast cancer patients SPARE Model is up to 40-50% more accurate than standard clinical markers in analysis with 1800+ samples for prediction of distant metastasis New... by admin | 22 May 2020 | News
New York and London, May 22, 2020 – Tiziana Life Sciences plc (NASDAQ: TLSA, AIM: TILS), a clinical stage biotechnology company developing targeted drugs for cancer, inflammatory diseases and COVID-19, today announces that it intends to demerge its StemPrintER... by admin | 21 May 2020 | News
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii: Tiziana Life Sciences Plc 1b. Please...